Advertisement
GSK vs JNJ
Which Stock Would AI Choose? GlaxoSmithKline (GSK) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- GSK has delivered solid recent momentum driven by pipeline advancements in vaccines and oncology, while offering a higher dividend yield compared to JNJ.
- JNJ reported strong Q1 2026 results with raised full-year guidance, contributing to superior year-to-date and one-year total returns versus broader market benchmarks.
- GSK trades at a more attractive valuation multiple, appealing to value-oriented investors in the healthcare sector.
- JNJ benefits from greater scale, diversified exposure across innovative medicines and medtech, and stronger overall price performance in recent market activity.
- Sector sentiment remains constructive for both companies amid ongoing innovation in respiratory, oncology, and infectious disease treatments.
- Relative positioning favors GSK in short-term trend consistency according to certain quantitative models, while JNJ demonstrates greater long-term stability.
Introduction
This comparison examines GSK and JNJ, two established healthcare companies with significant global operations in pharmaceuticals and related segments. Investors and traders focused on defensive sector exposure, dividend income, pipeline catalysts, and relative valuation may find the analysis relevant for portfolio allocation decisions. The review highlights recent performance trends, business models, and observable market factors without forward-looking projections.
GSK Overview and Recent Performance
GSK plc operates as a global biopharmaceutical company with a focus on specialty medicines, vaccines, and respiratory products. In recent market activity, the stock has shown resilience amid broader sector movements, with performance influenced by multiple clinical trial updates across its vaccine and oncology pipelines. Developments in areas such as respiratory syncytial virus (RSV) combinations, malaria prevention, and various cancer candidates have contributed to sentiment. The company maintains a competitive dividend yield, and upcoming second-quarter results scheduled for late July provide additional context for near-term evaluation. Overall, recent weeks reflect steady interest supported by innovation milestones rather than dramatic single-event shifts.
JNJ Overview and Recent Performance
Johnson & Johnson focuses on innovative medicines and medtech solutions following its consumer health separation. Recent market activity has featured strong price appreciation, aided by robust first-quarter 2026 financial results that included revenue growth exceeding expectations and an upward revision to full-year guidance. Performance has benefited from consistent execution in key therapeutic areas and operational stability. The stock has outperformed broader indices over the trailing year, reflecting sustained investor confidence in its diversified portfolio and cash-flow generation. Recent weeks have shown continued momentum within a defensive healthcare framework.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing artificial intelligence trading bots from a much larger pool of hundreds available on the platform. These bots trade thousands of different tickers across equities, with only those demonstrating the strongest alignment with prevailing market conditions earning placement in the trending section. Available bots exhibit wide variation in trading styles, strategies, timeframes, historical performances, and statistical profiles, allowing users to match specific risk tolerances and objectives. Performance metrics and backtested results provide transparent data points for evaluation. For more details on currently trending options, visit Trending AI Robots.
Head-to-Head Comparison
GSK and JNJ operate in overlapping healthcare spaces but differ in scale and emphasis. JNJ maintains substantially larger market capitalization and broader diversification across pharmaceuticals and medical devices, providing greater stability during volatility. In contrast, GSK offers a more concentrated focus on specialty medicines and vaccines, which can translate to higher sensitivity to clinical readouts and regulatory events. Recent momentum has favored JNJ on absolute returns, while GSK presents a more compelling valuation and yield profile. Risk factors include litigation exposure for both, though JNJ’s size may offer greater capacity to absorb such pressures. Market sentiment remains positive toward healthcare innovation overall, with trade-offs centered on growth consistency versus income and value characteristics.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative valuation, dividend characteristics, and near-term catalysts, Tickeron’s AI models currently assign a probabilistic preference to GSK over JNJ in the current environment. This positioning reflects GSK’s technical profile and value metrics relative to peers, though outcomes remain subject to evolving market conditions and company-specific developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and JNJ is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 6 bullish TA indicator(s).
- GSK’s TA Score: 5 bullish, 2 bearish.
- JNJ’s TA Score: 6 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -1.64% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -2.30% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.40%. For the same industry, the average monthly price growth was +12.67%, and the average quarterly price growth was +6.87%.
Reported Earning Dates
GSK is expected to report earnings on Jul 28, 2026.
JNJ is expected to report earnings on Jul 15, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.40% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | JNJ | GSK / JNJ | |
| Capitalization | 104B | 619B | 17% |
| EBITDA | 10.1B | 33.7B | 30% |
| Gain YTD | 9.483 | 25.553 | 37% |
| P/E Ratio | 14.07 | 29.78 | 47% |
| Revenue | 32.8B | 96.4B | 34% |
| Total Cash | 3.44B | 22.1B | 16% |
| Total Debt | 19.1B | 55B | 35% |
GSK | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 17 Undervalued | |
PROFIT vs RISK RATING 1..100 | 39 | 5 | |
SMR RATING 1..100 | 27 | 36 | |
PRICE GROWTH RATING 1..100 | 49 | 12 | |
P/E GROWTH RATING 1..100 | 78 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (17) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (81). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
JNJ's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (39). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
GSK's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as JNJ (36). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (49). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
JNJ's P/E Growth Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for GSK (78). This means that JNJ’s stock grew significantly faster than GSK’s over the last 12 months.
| GSK | JNJ | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 38% |
| Stochastic ODDS (%) | 3 days ago 46% | 3 days ago 46% |
| Momentum ODDS (%) | 3 days ago 67% | 3 days ago 39% |
| MACD ODDS (%) | N/A | 3 days ago 36% |
| TrendWeek ODDS (%) | 3 days ago 53% | 3 days ago 42% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 46% |
| Advances ODDS (%) | 14 days ago 62% | 11 days ago 44% |
| Declines ODDS (%) | 4 days ago 54% | 3 days ago 42% |
| BollingerBands ODDS (%) | N/A | 3 days ago 35% |
| Aroon ODDS (%) | 3 days ago 51% | 3 days ago 45% |
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.